Clinical trials: Acute Spinal Cord Injury (SCI)
Spinal Cord Injury
Cethrin in Acute Cervical Spinal Cord Injury
This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III study designed to evaluate the efficacy and safety of Cethrin as a treatment for acute cervical spinal cord injury.
- Trial name
- NCT02053883
- Testing
- Cethrin (BA-210)
- Sponsor
- BioAxone BioSciences, Inc.
Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other…
- Conditions
- Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion
- Trial name
- SB-SCI-001 (NCT04812431)
- Testing
- Neural precursor cells derived from human embryonic stem cell line
- Where
- 2 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- S.Biomedics Co., Ltd.
Acute Spinal Cord Injury (SCI)
Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury.
- Trial name
- NCT07722962
- Testing
- KP-100IT
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Kringle Pharma, Inc.
Acute Spinal Cord Injury (SCI), Spinal Cord Diseases
NG004 in Spinal Cord Injury Patients
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI.
- Conditions
- Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Central Nervous System Diseases, Nervous System Diseases
- Trial name
- SPROUT (NCT06817577)
- Testing
- NG004
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- NovaGo Therapeutics AG
Acute Spinal Cord Injury (SCI)
Expanded Access to Elezanumab
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT04278235
- Testing
- Elezanumab
- Sponsor
- AbbVie
Spinal Cord Injury (SCI)
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year.
- Trial name
- ELASCI (NCT04295538)
- Testing
- Elezanumab
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Acute Spinal Cord Injury (SCI)
Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury
Technophage identified a promising compound, Eletriptan hydrobromide, that intends to use as a repurposed drug, for the treatment of acute spinal cord injury (SCI) in human subjects.
- Trial name
- eSpine (NCT06677229)
- Testing
- Eletriptan HBr 40 mg
- Where
- 2 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Technophage, SA
Traumatic Cervical Acute Spinal Cord Injury
Pilot Study of the Neuro-Spinal Scaffold for the Treatment of AIS A Cervical Acute SCI
Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal ScaffoldTM for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5-T1 Neurological Levels The purpose of this study is to support an…
- Trial name
- NCT03105882
- Testing
- Neuro-Spinal Scaffold
- Where
- Canada
- Sponsor
- InVivo Therapeutics
Acute Spinal Cord Injury (SCI), Spinal Cord Diseases
NG004 in Incomplete Spinal Cord Injury Patients
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI.
- Conditions
- Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Spinal Cord Injuries, Trauma Nervous System
- Trial name
- SPROUT-2 (NCT07840196)
- Testing
- NG004
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 120 people
- Sponsor
- NovaGo Therapeutics AG
Spinal Cord Injury
Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries
Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function.
- Trial name
- NCT00073853
- Testing
- Autologous Incubated Macrophages (cell therapy)
- Where
- 7 sites in United States, Israel
- Volunteers
- 61 people
- Sponsor
- Proneuron Biotechnologies
Acute Traumatic Spinal Cord Injury
Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury
The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC (a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, HC016…
- Trial name
- SPINE (NCT02917291)
- Testing
- FAB117-HC, Control group
- Where
- 9 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Ferrer Internacional S.A.
Traumatic Thoracic Acute Spinal Cord Injury
The INSPIRE Study: Probable Benefit of the Neuro-Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury
This is an HDE probable benefit, open-label, non- randomized, single-arm, multicenter study to evaluate the safety and probable benefit of the poly(lactic-co-glycolic acid)-b-poly(L-lysine) Scaffold ("Scaffold") in subjects with…
- Trial name
- NCT02138110
- Testing
- Neuro-Spinal Scaffold
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- InVivo Therapeutics
Acute Spinal Cord Injury
AC105 in Patients With Acute Traumatic Spinal Cord Injury
The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.
- Trial name
- AC105 (NCT01750684)
- Testing
- AC105
- Volunteers
- 15 people
- Sponsor
- Acorda Therapeutics
Acute Spinal Cord Injury
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 6 dose regimens of ATI355 in acute spinal cord injury patients
- Trial name
- NCT00406016
- Testing
- ATI355
- Where
- 14 sites in Canada, Germany and 1 more
- Volunteers
- 52 people
- Sponsor
- Novartis